JP Morgan Chase’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $395M | Sell |
1,823,140
-192,869
| -10% | -$36.9M | 0.02% | 519 |
|
|
2026
Q1 | $378M | Buy |
2,016,009
+158,747
| +9% | +$29.3M | 0.02% | 484 |
|
|
2025
Q4 | $327M | Buy |
1,857,262
+588,912
| +46% | +$96.2M | 0.02% | 505 |
|
|
2025
Q3 | $178M | Buy |
1,268,350
+265,848
| +27% | +$35.9M | 0.01% | 738 |
|
|
2025
Q2 | $126M | Sell |
1,002,502
-461,218
| -32% | -$57.5M | 0.01% | 835 |
|
|
2025
Q1 | $200M | Sell |
1,463,720
-632,594
| -30% | -$90.4M | 0.01% | 669 |
|
|
2024
Q4 | $321M | Sell |
2,096,314
-3,161,009
| -60% | -$533M | 0.02% | 507 |
|
|
2024
Q3 | $1.02B | Buy |
5,257,323
+542,366
| +12% | +$113M | 0.08% | 235 |
|
|
2024
Q2 | $1.09B | Sell |
4,714,957
-5,187
| -0.1% | -$1.13M | 0.09% | 216 |
|
|
2024
Q1 | $1.02B | Sell |
4,720,144
-352,496
| -7% | -$82.6M | 0.09% | 233 |
|
|
2023
Q4 | $1.31B | Buy |
5,072,640
+86,888
| +2% | +$21.3M | 0.13% | 163 |
|
|
2023
Q3 | $1.28B | Buy |
4,985,752
+514,565
| +12% | +$138M | 0.14% | 147 |
|
|
2023
Q2 | $1.27B | Buy |
4,471,187
+362,324
| +9% | +$108M | 0.14% | 161 |
|
|
2023
Q1 | $1.14B | Buy |
4,108,863
+1,838,556
| +81% | +$509M | 0.14% | 162 |
|
|
2022
Q4 | $629M | Buy |
2,270,307
+166,390
| +8% | +$47M | 0.08% | 240 |
|
|
2022
Q3 | $562M | Buy |
2,103,917
+128,827
| +7% | +$27.4M | 0.08% | 248 |
|
|
2022
Q2 | $403M | Sell |
1,975,090
-200,467
| -9% | -$41M | 0.06% | 323 |
|
|
2022
Q1 | $458M | Sell |
2,175,557
-2,360,923
| -52% | -$513M | 0.06% | 329 |
|
|
2021
Q4 | $1.09B | Sell |
4,536,480
-1,068,817
| -19% | -$275M | 0.13% | 182 |
|
|
2021
Q3 | $1.59B | Buy |
5,605,297
+250,531
| +5% | +$82.1M | 0.2% | 119 |
|
|
2021
Q2 | $1.85B | Buy |
5,354,766
+1,467,865
| +38% | +$445M | 0.22% | 101 |
|
|
2021
Q1 | $1.09B | Buy |
3,886,901
+974,880
| +33% | +$263M | 0.15% | 160 |
|
|
2020
Q4 | $713M | Buy |
2,912,021
+838,296
| +40% | +$216M | 0.1% | 207 |
|
|
2020
Q3 | $586M | Buy |
2,073,725
+88,010
| +4% | +$24.5M | 0.1% | 208 |
|
|
2020
Q2 | $531M | Buy |
1,985,715
+528,920
| +36% | +$159M | 0.1% | 210 |
|
|
2020
Q1 | $461M | Buy |
1,456,795
+16,971
| +1% | +$5.15M | 0.11% | 196 |
|
|
2019
Q4 | $427M | Buy |
1,439,824
+510,618
| +55% | +$142M | 0.08% | 264 |
|
|
2019
Q3 | $216M | Sell |
929,206
-29,901
| -3% | -$6.96M | 0.04% | 415 |
|
|
2019
Q2 | $230M | Sell |
959,107
-828,233
| -46% | -$191M | 0.05% | 407 |
|
|
2019
Q1 | $422M | Sell |
1,787,340
-880,495
| -33% | -$277M | 0.09% | 253 |
|
|
2018
Q4 | $803M | Sell |
2,667,835
-141,554
| -5% | -$45.2M | 0.19% | 124 |
|
|
2018
Q3 | $993M | Buy |
2,809,389
+246,886
| +10% | +$85M | 0.19% | 116 |
|
|
2018
Q2 | $744M | Sell |
2,562,503
-508,348
| -17% | -$143M | 0.15% | 136 |
|
|
2018
Q1 | $841M | Buy |
3,070,851
+254,334
| +9% | +$78.9M | 0.18% | 130 |
|
|
2017
Q4 | $897M | Buy |
2,816,517
+331,988
| +13% | +$107M | 0.19% | 114 |
|
|
2017
Q3 | $770M | Buy |
2,484,529
+208,228
| +9% | +$61.7M | 0.17% | 126 |
|
|
2017
Q2 | $618M | Sell |
2,276,301
-1,341,260
| -37% | -$355M | 0.14% | 157 |
|
|
2017
Q1 | $989M | Sell |
3,617,561
-18,118
| -0.5% | -$5.12M | 0.23% | 92 |
|
|
2016
Q4 | $1.03B | Buy |
3,635,679
+21,207
| +0.6% | +$6.29M | 0.25% | 89 |
|
|
2016
Q3 | $1.13B | Buy |
3,614,472
+518,928
| +17% | +$154M | 0.28% | 76 |
|
|
2016
Q2 | $749M | Sell |
3,095,544
-689,683
| -18% | -$182M | 0.19% | 123 |
|
|
2016
Q1 | $985M | Sell |
3,785,227
-519,265
| -12% | -$137M | 0.25% | 80 |
|
|
2015
Q4 | $1.32B | Buy |
4,304,492
+357,790
| +9% | +$103M | 0.33% | 55 |
|
|
2015
Q3 | $1.15B | Sell |
3,946,702
-1,013,729
| -20% | -$335M | 0.31% | 63 |
|
|
2015
Q2 | $2B | Sell |
4,960,431
-892,604
| -15% | -$358M | 0.47% | 34 |
|
|
2015
Q1 | $2.47B | Sell |
5,853,035
-1,121,931
| -16% | -$442M | 0.56% | 24 |
|
|
2014
Q4 | $2.37B | Buy |
6,974,966
+51,993
| +0.8% | +$16.8M | 0.54% | 24 |
|
|
2014
Q3 | $2.29B | Sell |
6,922,973
-192,080
| -3% | -$63.3M | 0.54% | 28 |
|
|
2014
Q2 | $2.24B | Buy |
7,115,053
+930,103
| +15% | +$280M | 0.57% | 26 |
|
|
2014
Q1 | $1.89B | Sell |
6,184,950
-688,303
| -10% | -$218M | 0.52% | 27 |
|
|
2013
Q4 | $1.92B | Sell |
6,873,253
-1,905,162
| -22% | -$493M | 0.55% | 27 |
|
|
2013
Q3 | $2.11B | Sell |
8,778,415
-1,009,627
| -10% | -$226M | 0.63% | 20 |
|
|
2013
Q2 | $2.11B | Buy |
+9,788,042
| New | +$2.09B | 0.67% | 19 |
|
Other funds holding BIIB
JP Morgan Chase's BIIB Position: Q2 2026 in Review
JP Morgan Chase reduced its Biogen (BIIB) stake by 9.6% in Q2 2026, selling an estimated $36.9M and leaving 1,823,140 shares worth $395M. The position accounts for 0.02% of the portfolio, ranked #519.
JP Morgan Chase first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.47B in Q1 2015. 1,040 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- JP Morgan Chase held 1,823,140 shares of Biogen worth $395M as of Q2 2026.
- JP Morgan Chase sold 192,869 Biogen shares in Q2 2026, an estimated $36.9M.
- Biogen made up 0.02% of JP Morgan Chase's portfolio in Q2 2026, its #519 holding.
- JP Morgan Chase first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
- JP Morgan Chase's Biogen position peaked at $2.47B in Q1 2015.
- 1,040 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.